Dr. Mohtashim Shamsi, Southern Illinois University, finalized his 2-year project with NDR. Shamsi investigated the feasibility of using label-free electrochemical detection methods to detect RAN and NfL in serum for patients with ALS. The proof-of-concept study facilitates a low cost point of care biosensing platform for clinical use. Future development of the graphene-modified low cost multiplexed wax-on-plastic biosensing chips include expanding the repertoire of ALS-associated proteins detected in the serum. The future of this technology is in stratifying patients in ALS studies to facilitate getting the right treatment to the right patient. We congratulate Dr. Shamsi on receiving a grant to continue his work on this important topic.
top of page
Recent Posts
See AllNDR contributed to the work that was published by Dr. Adriano Chaves-Filho and the Dr. Sayuri Miyamoto team. To profile oxylipins in amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative dise
6
Neurodegenerative disease research is pleased to announce the progress of developing TVALA for the treatment of neuroinflammation in ALS. You can read about the trial and follow our progress .
22
Indiana University researcher Chandler Walker, Ph.D., developed a stem cell-based secretome therapy that influences both the central and peripheral components of Amyotrophic Lateral Sclerosis (ALS) pa
27
bottom of page